Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Professor Awarded $5.6 Million NIH Grant to Develop Therapeutics Against Deadly Viruses

24.06.2008
Researchers at the Uniformed Services University of the Health Sciences (USU) have been awarded a $5.6 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop and test vaccines and treatments for the Nipah and Hendra viruses.

Dr. Christopher C. Broder, USU professor of microbiology and immunology and director of the university’s interdisciplinary program in Emerging Infectious Diseases, is the principal investigator of the grant from NIAID. The grant was awarded to further develop the vaccines and therapeutics for Nipah and Hendra that his group has been working on for the past several years.

The award will support a continued collaboration with investigators Lin-Fa Wang, Ph.D. and Deborah Middleton M.V.Sc, Ph.D. of Australia’s Commonwealth Scientific and Industrial Research Organization (CSIRO) Livestock Industries, Australian Animal Health Laboratory (AAHL) and Australian Biosecurity Cooperative Research Center (AB-CRC) in Geelong, Victoria, where there is a high-level biosafety and security facility for testing the vaccines and therapeutics against these deadly viruses in appropriate models.

Hendra virus and Nipah virus are recently emerged paramyxoviruses that are highly pathogenic and can cause lethal infections in several animals and in humans. Since their initial discovery in Australia and Malaysia, sporadic Hendra outbreaks have been reported from 1995 to 2007, while Nipah has caused at least 9 outbreaks between 1998 and 2008. The majority of these episodes have occurred on a regular basis in Bangladesh and India, with human case fatality rates approaching 75% along with evidence of human-to-human transmission. The most recent appearance of Nipah in 2008 claimed the lives of several children. Studies have demonstrated that the natural reservoirs for Hendra and Nipah viruses are bats, primarily several different species of large fruit bats commonly referred to as flying foxes.

... more about:
»Hendra »NIH »Nipah »Vaccine »therapeutic

The first steps in countering infections caused by these viruses were to develop a vaccine that was both safe and effective, and also to find antibodies that could neutralize them. In earlier work, also supported by NIAID through the Middle-Atlantic Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (MARCE), a subunit vaccine for Nipah and Hendra, composed of a piece of the virus known as the G glycoprotein, was developed by Dr. Katharine Bossart, a former graduate student of Broder’s laboratory. Recent experiments by Dr. Bossart and colleagues have shown the vaccine to be very effective in preventing Nipah virus disease.

Antibodies on the other hand are proteins that are found in blood or other bodily fluids of animals and humans that are used by the immune system to identify and neutralize foreign molecules, including bacteria and viruses.

The neutralization of an invading virus is the process by which an antibody can specifically bind and block its infection, and in other recent MARCE-supported studies carried out by Broder’s group in collaboration with Dimiter S. Dimitrov, Ph.D., of the National Cancer Institute’s, Center for Cancer Research in Frederick, Md., and Zhongyu Zhu, Ph.D., of Dimitrov's group, a very potent Nipah and Hendra virus neutralizing human monoclonal antibody (m102.4) was developed as a potential therapeutic that could be administered to people infected by these viruses.

“We now have the critical resources needed to evaluate the therapeutic potential of both vaccines and perhaps more importantly a potent human antibody against both Nipah virus and Hendra virus, that could help control outbreaks in geographical regions susceptible to these emerging viruses, and result in a real benefit to those people at risk of infection and disease caused by these deadly agents," said Broder. “Our success in obtaining these new critical funds is also evidence of the success of NIAID’s Regional Center of Excellence program,” Broder added.

This NIH award will also support and bring together the expertise to structurally characterize the interaction between the Nipah and Hendra virus and the receptor proteins on cells that serve the gateway for virus infection, led by Dimitar B. Nikolov, Ph.D., and Kai Xu of Nikolov’s team at the Structural Biology Program of the Memorial Sloan-Kettering Cancer Center, in New York. Information from these additional studies may lead to the discovery of new therapeutics targeting the virus-host cell infection process.

NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. It also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and allergies.

Located on the grounds of Bethesda’s National Naval Medical Center and across from the National Institutes of Health, USU is the nation’s federal school of medicine and graduate school of nursing, and also offers several graduate programs in the biomedical sciences and public health. The university educates health care professionals dedicated to career service in the Department of Defense and the U.S. Public Health Service. Medical students are active-duty uniformed officers in the Army, Navy, Air Force and Public Health Service, who are being educated to deal with wartime casualties, natural disasters, emerging infectious diseases, and other public health emergencies. Of the university’s more than 4,000 physician alumni, the vast majority serve on active duty and are supporting operations in Iraq, Afghanistan, and elsewhere, offering their leadership and expertise.

Office of External Affairs | newswise
Further information:
http://www.usuhs.mil

Further reports about: Hendra NIH Nipah Vaccine therapeutic

More articles from Life Sciences:

nachricht Designer cells: artificial enzyme can activate a gene switch
22.05.2018 | Universität Basel

nachricht Flow of cerebrospinal fluid regulates neural stem cell division
22.05.2018 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

Im Focus: Entangled atoms shine in unison

A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.

The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

Designer cells: artificial enzyme can activate a gene switch

22.05.2018 | Life Sciences

PR of MCC: Carbon removal from atmosphere unavoidable for 1.5 degree target

22.05.2018 | Earth Sciences

Achema 2018: New camera system monitors distillation and helps save energy

22.05.2018 | Trade Fair News

VideoLinks
Science & Research
Overview of more VideoLinks >>>